Dehydrobenzperidol and disopyramide in A-V conduction

Area of Science:

• Cardiovascular Pharmacology
• Electrophysiology

Background:

• Understanding drug effects on cardiac conduction is crucial for patient safety.
• Dehydrobenzperidol (Droperidol) and disopyramide are used clinically, but their precise electrophysiological effects require detailed study.

Purpose of the Study:

• To investigate the electrophysiological effects of Droperidol and disopyramide on atrioventricular (A-V) conduction.
• To differentiate the effects of varying doses of these drugs on cardiac impulse propagation.

Main Methods:

• Anesthetized, open-chest dogs were used, with cardiac pacing.
• His's bundle electrograms were recorded using catheter or sutured plaque electrodes.
• Intravenous administration of Droperidol (0.35, 1.0 mg/kg) and disopyramide (1, 5, 10 mg/kg).

Main Results:

• Droperidol at 0.35 mg/kg had no effect on conduction.
• A higher Droperidol dose (1.0 mg/kg) prolonged atrial-His conduction but not His-ventricular conduction.
• Disopyramide at 5 and 10 mg/kg significantly prolonged both atrial-His and His-ventricular conduction times.

Conclusions:

• Droperidol exhibits minimal effects on A-V conduction at clinically relevant doses.
• Disopyramide demonstrates a dose-dependent direct depressant effect on cardiac conduction, overriding its atropinic properties.